Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial
Holland et al., The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(22)00215-6
https://c19early.org/holland.html